The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab

SIMPLE SUMMARY: Atezolizumab plus bevacizumab has been approved as the first-line systemic treatment for unresectable hepatocellular carcinoma (uHCC) patients. However, the real-world practice of this combination is limited. We reported 48 uHCC patients who received atezolizumab plus bevacizumab, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jing-Houng, Chen, Yen-Yang, Kee, Kwong-Ming, Wang, Chih-Chi, Tsai, Ming-Chao, Kuo, Yuan-Hung, Hung, Chao-Hung, Li, Wei-Feng, Lai, Hsiang-Lan, Chen, Yen-Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774110/
https://www.ncbi.nlm.nih.gov/pubmed/35053508
http://dx.doi.org/10.3390/cancers14020343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774110/
https://www.ncbi.nlm.nih.gov/pubmed/35053508
http://dx.doi.org/10.3390/cancers14020343

Ejemplares similares